Roche Holding AG is bracing for slower earnings growth this year as its ageing cancer blockbusters face competition and the Swiss drugmaker readies a new generation of medicines. The world’s biggest maker of cancer drugs is pushing out new treatments such as the cancer immune therapy Tecentriq to buoy earnings as it faces the prospect of biosimilar competition for its top sellers Rituxan, Herceptin and Avastin, targeted tumor therapies that were revolutionary when they were first approved in the late 1990s and mid-2000s.
Category: Lung Cancer
This Promising Prostate Cancer Treatment Could Be a Game-Changer
Cancer is among the scariest diagnosis a person can receive. According to the American Cancer Society’s “Cancer Facts & Figures 2016” report, there were an estimated 1.69 million new cases of cancer diagnosed in 2016, along with a projected 595,690 cancer deaths.
This Promising Prostate Cancer Treatment Could Be a Game-Changer
Cancer is among the scariest diagnosis a person can receive. According to the American Cancer Society’s “Cancer Facts & Figures 2016” report, there were an estimated 1.69 million new cases of cancer diagnosed in 2016, along with a projected 595,690 cancer deaths.
Bristol-Myers Falls Further Behind Merck in Lung Cancer Race
Bristol-Myers Squibb Co. fell after the drugmaker said it wouldn’t seek accelerated approval for a combination of its drugs to treat first-line lung cancer.
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
Years before becoming a top cancer specialist, Eric Winer used to save money on his own medical care by talking U.S. pharmacists into giving him expired treatments for free. Winer, who has a bleeding disorder known as hemophilia, knew the drugs would still work for a brief time after the official use-by date.
Ono Pharma’s Wild 2016 Ride Cuts Stock Valuation by $16 Billion
Having surged as much as 34 percent as of mid-April, the stock finished the year down more than 41 percent, marking its worst performance in more than 50 years. The swing reduced its market capitalization by about 1.87 trillion yen from a record high in April.